Efficient and Accurate Preliminary Screening Kit for Kidney Disease with 94% Accuracy

2023-06-08 08:51:00

Research “Preliminary Screening Kit for Kidney Disease” from the urinary albumin test. It was found to have high efficiency, accuracy, 94% accuracy, 96% sensitivity, 97.8% specificity. It passed the FDA and proposed to be included in the gold patent. But there is a risk of knowing the results quickly. Prevent kidney deterioration in the early stages.
On June 8, Prof. Dr. Nuttachai Srisawat, professor of the Department of Internal Medicine Faculty of Medicine Chulalongkorn University The researcher network of the Health Systems Research Institute (HSRI) said that the patient report data Hospitals under the Ministry of Public Health (Sor.) In 2021, there were as many as 1,007,251 patients with chronic kidney disease, with an increasing trend. Due to eating habits and taking medicines to treat chronic non-communicable diseases (NCDs), such as diabetes, high blood pressure Urinary tract disease The severity of chronic kidney disease is divided into 5 stages according to the efficiency of the kidneys. The treatment for phases 1-4 is changing eating and lifestyle behaviors such as refraining from smoking, reducing salty foods, limiting protein foods, etc., but phase 5 or the last phase. Kidney replacement therapy must also be included. However, early stage kidney disease is often asymptomatic. Disease screening has to detect the value. “Serum creatinine” and only detect microalbumin in urine. This is because albumin is usually not detected in the urine. because the kidneys can filter and store If albumin is detected in the urine, it means the glomerular filtration efficiency is decreased. and risk of chronic kidney disease

“To examine with this method, the patient must come to the hospital, although it will take a short time to examine. But it takes time and has travel expenses. especially patients in remote areas My team and I have conducted a research project to develop a screening system for early chronic kidney disease in primary care with albuminuria testing kits, supported by HSRI research funding, to evaluate the efficiency of the testing kits. in asymptomatic volunteers but there are risk factors for early chronic kidney disease Older than or equal to 60 years old with diabetes or high blood pressure together with a total of 2,313 cases, “said Dr. Nuttachai.

Dr. Nuttachai said The results showed that 595 volunteers or 25.72% met the criteria for suspected chronic kidney disease. It was found that the abnormal urinary albumin/creatinine content was greater than the number of subjects with abnormal glomerular filtration rate. Urinalysis is important in early screening for chronic kidney disease. especially those with normal glomerular filtration. As for the results of testing for albumin in urine with a strip kit, it was found that The mean accuracy was 94%, the mean sensitivity was 86%, the mean specificity was 97.8%, the mean PPV was 88.2% and the mean NPV was 97.4%. which is the initial symptom of chronic kidney disease

“A test kit developed by the research team It is considered efficient and highly accurate, convenient to use, and reads results quickly. It is an ATK screening test, so it can be used to screen for chronic kidney disease in the early stages by yourself. Helps reduce the cost of traveling to the hospital. The test kit can also be used in the field, community hospitals, or STD hospitals that lack laboratory equipment conveniently. More people have access to screening for kidney disease, “said Dr. Nuttachai.

Dr. Nuttachai said The policy proposal is The screening kit for kidney disease should be brought into the gold patent. To be used in primary care facilities that are closest to the public, such as the National Health Service Hospital or the Public Health Service Center (Public Health Service Center), will help people know the albumin value that indicates kidney disease since plant realized Modify eating and lifestyle behaviors In order to lead to a reduction in the number of patients with end-stage chronic kidney disease in the big picture, the test kit has been registered with the Food and Drug Administration (FDA) and can cooperate with the private sector to produce commercially for sale. Currently, it is in the process of reviewing the legal requirements with the private sector interested in becoming a distributor.